Using molnupiravir as an example again, we look at the new data that's been released and the FDA's analysis. Why is the data released showing something different to the interim analysis only a fortnight or so ago? And why does this seem to happen a lot, with early results being more positive than the later full results? And what does this mean for us and how we think about using early data?